NovaMedica: Relonova (migraine medicine)

Main article: Migraine

2023: Drug Registration

The Russian pharmacists developed and registered a cure for. migraines This was Rusnano reported on March 21, 2023.

The drug "Relonova" of the company "NovaMedica" is designed to stop headache in case of migraine attacks. According to the company, this is the first drug in Russia based on the risotriptan molecule, the production of which is completely localized in the country - from development to production and introduction into the practice of appointment by specialists.

Relonova will be produced in Moscow - at the facilities of the NovaMedica Innotech Technological Center (a 100% subsidiary of NovaMedica), which will ensure uninterrupted supply of medicines and its availability to Russian patients.

Migraine is a socially significant disease, which is due to its wide prevalence and negative impact on the quality of life of patients. According to the World Health Assembly, migraines are in second place after stroke among neurological diseases that lead to disability and death, as well as to a reduction in healthy and productive years of life. The drug "Relonova" is intended for the urgent treatment of headache in migraine attacks in patients over 18 years of age. It can also be used for a long history of migraine, when the effectiveness of other analgesics is significantly reduced. The drug will be produced in the form of tablets with a dosage of 10 mg and sold in pharmacies on prescription.

We sought to give Russian doctors and patients uninterrupted access to a modern therapy at an affordable price and ensured its full localization in Russia. The creation of the drug "Relonova" makes an important contribution to the development of drug provision for Russian patients. This is the fourth drug registered by our company over the past year, - said Elena Litvinova, General Director of NovaMedica.